Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biodesix (BDSX) Other Non-Current Liabilities (2019 - 2025)

Historic Other Non-Current Liabilities for Biodesix (BDSX) over the last 7 years, with Q3 2025 value amounting to $769000.0.

  • Biodesix's Other Non-Current Liabilities rose 2403.23% to $769000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $769000.0, marking a year-over-year increase of 2403.23%. This contributed to the annual value of $815000.0 for FY2024, which is 1446.63% up from last year.
  • As of Q3 2025, Biodesix's Other Non-Current Liabilities stood at $769000.0, which was up 2403.23% from $549000.0 recorded in Q2 2025.
  • Biodesix's 5-year Other Non-Current Liabilities high stood at $30.9 million for Q1 2021, and its period low was $549000.0 during Q2 2025.
  • In the last 5 years, Biodesix's Other Non-Current Liabilities had a median value of $12.2 million in 2022 and averaged $10.7 million.
  • In the last 5 years, Biodesix's Other Non-Current Liabilities soared by 3408.12% in 2023 and then crashed by 9624.4% in 2024.
  • Over the past 5 years, Biodesix's Other Non-Current Liabilities (Quarter) stood at $16.0 million in 2021, then increased by 16.33% to $18.6 million in 2022, then tumbled by 96.18% to $712000.0 in 2023, then rose by 14.47% to $815000.0 in 2024, then fell by 5.64% to $769000.0 in 2025.
  • Its Other Non-Current Liabilities was $769000.0 in Q3 2025, compared to $549000.0 in Q2 2025 and $692000.0 in Q1 2025.